Key Takeaways
- India steady, U.S. stalled, new bets drag: India formulations grew in line with the market while the chronic portfolio outperformed by 640 bps, but U.S. growth is held back by a single-product price hit and a regulatory freeze on new approvals.
- Margin guidance held, not raised: H1 EBITDA ran comfortably above the 20%-21% guided range, yet management kept the full-year band, citing an 80 bps Occlutech dilution and uncertain Enzene recovery.
- Enzene pivot from biosimilars to CDMO: The denosumab BLA delay and biosimilar price erosion have forced a strategic reset; Enzene will now be run as a CDMO-first business, a shift that resets both the growth path and the investment case.
- Daman remediation is the single biggest unlock: Eight products filed from the OAI-hit site are due for launch in the next 6-12 months; until the FDA schedules a re-audit, a material U.S. revenue lever stays frozen.
- What to watch next quarter: Whether the FDA responds on Daman re-audit timing, the pace of Enzene's H2 loss reduction, and any early signal on tolvaptan's trajectory now that it has a full quarter of sales.
India Business: Chronic Outperformance, Trade Generics Reset
- Chronic engine running ahead of the market: The chronic portfolio grew 22.4% versus 16% for IPM, a 640 bps outperformance driven by anti-diabetic, cardiovascular, neuropsychiatry, dermatology, multivitamins, urology and respiratory therapies.
- Acute in line, but the whole-India story is bigger than IQVIA: Acute growth tracked IPM acute, so total India growth appeared to match the market, but that comparison excludes trade generics, which sit outside IQVIA coverage.
- Trade generics growth slowed deliberately: Competitive intensity rose as all large players entered the segment, and Alkem tightened its own credit policies while lapping a large base; management expects some improvement in H2 and is entering the animal generics side, though the outcome is uncertain.
- VMN and semaglutide leadership: VMN is now the number-one brand per IQVIA, and the semaglutide injectable leads on volumes, though not yet on value.
- Full-year India growth target: Management expects to end FY27 at close to 11% overall India growth.
Amrut Naik: "I do not think the fundamentals of the business are different. Obviously, the dynamics in India is different, and I do think that we have a great team here... the market-beating growth that we have committed to the investor community, I think that we will continue to demonstrate that in India."
U.S. Business: Price Erosion Concentrated, Approvals Frozen
- Volume up, price down, growth flat: U.S. volumes expanded over 10%, but price erosion of about 16% was partially offset by new product launches to an extent of 3%; a 3% constant-currency contraction flipped to 2% reported growth because of a currency tailwind.
- The price hit is a single-product story: The 16% erosion was driven entirely by Sacuval, not a broad-based U.S. pricing deterioration.
- Daman OAI status is the bottleneck: The facility's regulatory status does not affect inline products, but it has stalled new approvals; eight products filed from Daman are due for launch in the next 6-12 months, and three important products' approvals are delayed. All remediation responses have been submitted to the FDA, and management is waiting for a counter-response on re-audit timing.
- Recent launches underperformed: Dapagliflozin and its metformin combination, the only two products launched under the OAI-impacted period, did not pick up to anticipated levels and were described as suboptimal.
- Tolvaptan ramp-up will be slow: Launched in September, the product is restricted by a REMS program that limits distribution to selected outlets and pharmacies; management explicitly stated it will not be close to Lupin's numbers and is unlikely to contribute meaningfully in the next two quarters.
- Full-year U.S. outlook: Mid-single-digit constant-currency growth is expected for FY27, with H2 slightly better than H1; new launches are not expected to meaningfully raise revenue guidance until Daman is resolved.
Sandeep Singh: "I know we look at Lupin's, and we all get excited, Lupin's numbers, but it is not going to be close to that. Let us give it a quarter to see how it is. But right now, we are not anywhere close to having a very meaningful contribution."
Enzene: Strategic Reset from Biosimilars to CDMO
- A disappointing quarter, a bigger pivot: Enzene revenue degrew 35% due to the lumpy nature of CDMO business, the denosumab BLA delay in the U.S., and worse-than-expected price erosion in the India biosimilars B2B business.
- The denosumab setback is regulatory, not structural: U.S. approval was delayed because the FDA raised analytical queries requiring some methods to be redone; a refiling is needed. The EU approval is already in hand, but a commercial partner with oncology focus must be found, as the existing Theramex partnership covers only women's healthcare.
- CDMO is now the primary identity: Management stated that Enzene going forward will be a CDMO play rather than a biosimilar play, and the biosimilar pipeline will not be as important; the business must be evaluated with a different lens than the Alkem parent.
- U.S. plant is partially operating, H2 expected better: The plant is not idle, with some CDMO business running; H2 will be far busier than H1, and the quarter's losses should not be annualized. The key milestone is FDA site approval tied to a BLA, which remains in a gray area until that happens.
- Financial path: Enzene revenue is expected to roughly double in four years, with EBITDA breakeven in a year and a half to two years maximum; capex of INR 300-350 crore is largely done. Management would rather trade growth for breaking even.
Sandeep Singh: "Enzene, as we go forward, will be a more CDMO rather than a biosimilar play. Therefore, I think the biosimilar pipeline will not be that important for Enzene... it is a different business than the Alkem parent's business, so we will have to use a different lens."
MedTech & International Markets: Occlutech Consolidation, LATAM Momentum
- Occlutech integrated, margin-dilutive for now: The acquisition was consolidated from 16 July, adding approximately INR 1,100 crore in intangibles and INR 700 crore in goodwill; it diluted consolidated EBITDA margin by 80 bps this quarter, with PPA depreciation of close to INR 28 crore and interest costs that will persist.
- The U.S. is the real prize, but it is a 2028 story: Occlutech's current U.S. presence is insignificant; a major ramp-up is expected when U.S. products launch, likely in 2028. The business is expected to exit its EBITDA drag in a year and grow 3x in five to six years, though that growth will be back-ended.
- Non-U.S. international markets delivered steady growth: LATAM led, with Colombia and Mexico as key Q2 drivers; Chile and Australia also performed well. Strong double-digit growth is expected in H2, with a full-year weighted average in the mid-to-high teens and mid-teens growth next year on a higher base.
- Europe picking up: Germany and the U.K. are expected to contribute to the H2 international acceleration.
Margins: Guidance Held Despite a Strong First Half
- H1 ran ahead of the guided range, but management will not raise: H1 EBITDA margin was comfortably above the higher end of the 20%-21% band, yet the full-year guidance was held, with management calling a revision premature given Occlutech's 80 bps dilution and uncertainty around Enzene's recovery pace.
- Core pharma margin aspiration intact: The core pharma business aims for 100 bps year-on-year improvement on reported margins, subject to geopolitical factors and the minimum import price impact.
- FY27 EBITDA margin expected at best on par with FY26: At approximately 20.4%, possibly marginally lower; Q3 and Q4 may face margin pressures from the full MIP impact flowing through and the ongoing drag from new businesses.
- From FY28, a structural margin climb begins: Management expects more than 50 bps improvement every year, driven by meaningful operational leverage from domestic and international growth as Enzene and MedTech drags fade.
- R&D spend lumpy but guided: R&D jumped this quarter due to ordering of reference listed drugs; the full-year guidance of 4%-4.5% of revenue is maintained, with Q4 typically the highest quarter.
Sandeep Singh: "I would rather trade growth for breaking even."
Regulatory & Cost Watchpoints
- Mandva API facility cleared clean: A U.S. FDA inspection concluded with no Form 483 observations, a positive data point amid the Daman overhang.
- Daman gaps are procedural, not capital-intensive: The observations were procedural rather than infrastructural, so remediation carries no material cost; all responses are with the FDA, and the company is waiting for a re-audit schedule.
- Penicillin MIP impact still to come: The full impact of the minimum import price on Pen G and amoxicillin+clavulanic acid has not yet hit the P&L because of old inventory; it will be felt in H2 and is already baked into the EBITDA margin guidance.
- Denosumab biosimilar EU approval is an unused asset: The product is approved in the EU but needs a commercial partner with oncology capabilities, distinct from the existing Theramex relationship.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| EBITDA margin | 20%-21% for FY27; not revised despite H1 outperformance | FY27 full year |
| Core pharma margin improvement | 100 bps YoY on reported margins, subject to geopolitics and MIP impact | FY27 |
| Structural margin expansion | 50 bps+ improvement every year from FY28 onward | Starting FY28 |
| India revenue growth | Close to 11% overall growth | FY27 full year |
| U.S. revenue growth | Mid-single-digit constant-currency growth; H2 slightly better than H1 | FY27 full year |
| Non-U.S. international growth | Strong double-digit H2; full-year weighted average mid-to-high teens | FY27 full year |
| Enzene EBITDA breakeven | Breakeven in 1.5-2 years maximum | By FY29 |
| Enzene revenue | Roughly double in size | In four years |
| MedTech EBITDA drag exit | Come out of EBITDA drag | In one year |
| MedTech revenue | 3x current size | In five to six years |
| R&D spend | 4%-4.5% of revenue | FY27 |
| Enzene capex | INR 300-350 crore, largely done | Over next three years |
| MedTech capex | Close to INR 400 crore | Over next three to four years |
| Daman product launches | ~8 products filed from Daman due for launch, contingent on FDA re-audit | Next 6-12 months |
| Tolvaptan contribution | Not expected to be meaningful | Next two quarters |
Key Metrics
| Metric | Q2 FY27 |
|---|---|
| Revenue from operations | ₹4,520 cr, +13.8% YoY |
| EBITDA | ₹1,025 cr, +11.3% YoY |
| EBITDA margin | 22.5%, vs 20.4% in FY26; Occlutech diluted margin by 80 bps this quarter |
| Core pharmaceutical EBITDA margin | ~26% in Q2, noted as seasonally high |
| R&D expenses | 4.3% of revenue; full-year guidance 4%–4.5% |
| Profit before tax | +7.7% YoY |
| Net profit | -11.7% YoY |
| Net cash | ₹4,900 cr+ |
| India business IQVIA growth | 13.8% YoY, at par with IPM |
| Acute segment growth | 12.1% YoY, vs IPM 12.3% |
| Chronic segment growth | 22.4% YoY, vs IPM 16%, 640 bps outperformance |
| International business growth | 22.3% YoY |
| U.S. business growth | 2% YoY in reported terms; -3% in constant currency; volume +10%, price erosion ~16% |
| Non-U.S. business growth | 58% YoY; ex-Occlutech H1 growth 31%, full-year expected mid-teens to higher teens |
| Biotech (Enzene) sales | ₹70 cr, -35% YoY |
| MedTech sales | ₹133 cr, includes Occlutech consolidated from 16 July |
| India business full-year growth guidance | ~11% |
| U.S. business full-year growth guidance | Mid-single digit in constant currency |
| FY27 EBITDA margin guidance | At best on par with FY26 (~20.4%), possibly marginally lower |
| Pending ANDAs (U.S.) | 23 pending ANDAs, 18 tentative approvals; ~8 products from Daman due for launch in 6–12 months |
| Occlutech identifiable intangibles | ₹1,100 cr, amortized over 10 years; goodwill ₹700 cr |
| Occlutech PPA depreciation | ₹28 cr for the quarter, to continue in subsequent quarters |
| Enzene + MedTech combined capex | ₹600–700 cr over next 3–4 years |
| India chronic mix | ~24–25% of portfolio, vs industry ~65/35 acute/chronic |